Keywords: کمیته دارویی برای استفاده انسانی; European regulation model; HMP; EU monograph; TUR; WEU-MA; ESCOP; European Scientific Cooperative on Phytotherapy; WHO; World Health Organization; EU; European Union; HMPs; herbal medicinal products; WEU-MAs; marketing authorizations; TURs; traditional us
مقالات ISI کمیته دارویی برای استفاده انسانی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کمیته دارویی برای استفاده انسانی; ADA; anti-drug antibodies; CHMP; Committee for Medicinal Products for Human Use; DIN; Drug Identification Number; ECCO; European Crohn's and Colitis Organisation; EMA; European Medicines Agency; FDA; Food and Drug Administration; INN; International Nonp
Keywords: کمیته دارویی برای استفاده انسانی; Triterpene glycosides; Adjuvant; Cancer; Targeted toxins; Antimicrobial; Anti-inflammatory; Vaccines; QS-21; AD; Alzheimer's disease; AIDS; acquired immune deficiency syndrome; AS; adjuvant system; Aβ; amyloid β; APC; antigen presenting cells; Api; apio
Keywords: کمیته دارویی برای استفاده انسانی; Cell therapy; Minimally manipulated; Homologous use; Health Canada; Food and Drugs Act; Food and Drug Regulations; AHR Act; Assisted Human Reproduction Act of Canada; BGTD; Biologics and Genetic Therapies Directorate; CBER; Center for Biologics Evaluation
Keywords: کمیته دارویی برای استفاده انسانی; CFR; Code of Federal Regulations; CHMP; Committee for Medicinal Products for Human Use; COMP; Committee for Orphan Medicinal Products; EC; European Commission; EMA; European Medicines Agency; EU; European Union; FDA; Food and Drug Administration; MHLW; Mi
Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges
Keywords: کمیته دارویی برای استفاده انسانی; ACR; American College of Rheumatology; ADAb; anti-drug antibody; ADCC; antibody-dependent cell-mediated cytotoxicity; AIFA; Italian Medicines Agency; CDC; complement-dependent cytotoxicity; CHMP; Committee for Medicinal Products for Human Use; DAS28; 28-j
Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments
Keywords: کمیته دارویی برای استفاده انسانی; ACR; American College of Radiology; AD; Alzheimer disease; ADNI; Alzheimer's Disease Neuroimaging Initiative; ALS; Amyotrophic Lateral Sclerosis; ASD; Autism Spectrum Disorder; BBB; Blood-Brain-Barrier; BEST; Biomarkers, Endpoints and other Tools; BLA; Bi
Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial
Keywords: کمیته دارویی برای استفاده انسانی; AE; adverse event; AESI; adverse event of specific interest; AS; adjuvant system; CBER; Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; EMA; European Medicines Agency; GMT; geome
Changing paradigms in bioequivalence trials submitted to the EMA for evaluation - A clinical and regulatory perspective
Keywords: کمیته دارویی برای استفاده انسانی; EU; European Union; MA; marketing authorisation; BE; bioequivalence; BCS; Biopharmaceutics Classification System (BCS); CHMP; Committee for Medicinal Products for Human Use; NHS; National Health System; API; active pharmaceutical ingredient; EMA; European
Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction
Keywords: کمیته دارویی برای استفاده انسانی; AUC; area under the plasma concentration-time curve; CHMP; Committee for Medicinal Products for Human Use; EGFR; epidermal growth factor receptor; FDA; Food and Drug Administration; FVB; Friend Leukemia Virus; HER; human epidermal growth-factor receptor
Physicians prefer greater detail in the biosimilar label (SmPC) - Results of a survey across seven European countries
Keywords: کمیته دارویی برای استفاده انسانی; Regulatory requirements; Biosimilars; Labelling survey; Physician preference; ASBM; Alliance for Safe Biologic Medicines; CHMP; Committee for Medicinal Products for Human Use; EMA; European Medicines Agency; EPAR; European Public Assessment Report; GaBI;
Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults
Keywords: کمیته دارویی برای استفاده انسانی; aIIV3; adjuvanted trivalent inactivated influenza vaccine; IIV3; inactivated trivalent influenza vaccine; PPSV23; 23-valent pneumococcal polysaccharide vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; HI; hemagglutination inhibition; GMT; geometr
Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years
Keywords: کمیته دارویی برای استفاده انسانی; AEs; adverse events; CBER; US Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CIs; confidence intervals; GMTs; geometric mean titers; HA; hemagglutinin antigen; HI; hemagglutination-inhibition; MAEs; med
Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: A phase IV, randomized, open-label, controlled study
Keywords: کمیته دارویی برای استفاده انسانی; AS03; H5N1 vaccine; Pandemic influenza; Korean adults; AEs; adverse events; CBER; US Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; EMA; European Medicines Agency; FDA; US Food
RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap
Keywords: کمیته دارویی برای استفاده انسانی; CHMP; Committee for Medicinal Products for Human Use; CSP; circumsporozoite protein; EMA; European Medicines Agency; GFATM; Global Fund to Fight Aids, Tuberculosis and Malaria; HBsAg; hepatitis B virus surface antigen; ITT; intention-to-treat; JTEG; Joint
An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age
Keywords: کمیته دارویی برای استفاده انسانی; AEs; adverse events; CBER; Center for Biologics Evaluation & Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; GMFR; geometric mean fold rise; GMT; geometric mean titer; HA; hemagglutinin; HI; hemagglutination inhibi
Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial
Keywords: کمیته دارویی برای استفاده انسانی; ATP; according to protocol; BARDA; Biomedical Advanced Research and Development Authority; BMI; body mass index; CBER; Center for Biologics Evaluation & Research; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; GMFR; geometr
A prospective observational safety study on MF59® adjuvanted cell culture-derived vaccine, Celtura® during the A/H1N1 (2009) influenza pandemic
Keywords: کمیته دارویی برای استفاده انسانی; AE; adverse event; AESI; adverse event of special interest; CHMP; Committee for Medicinal Products for Human Use; EMA; European Medicines Agency; HLT; High Level Term; PT; Preferred Term; SAE; serious adverse event; SOC; System Organ Class; WHO; World Hea
Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials
Keywords: کمیته دارویی برای استفاده انسانی; AE; adverse event; AS03; oil-in-water emulsion based adjuvant system; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; GMFR; geometric mean fold rise; GMT; geometric mean titre; GSK; GlaxoSmithKline; HA; haemagglutinin antige
Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: A prospective cohort study
Keywords: کمیته دارویی برای استفاده انسانی; AEs; adverse events; AESI; adverse events of special interest; AS03; oil-in-water emulsion-based Adjuvant System AS03; CDC; Centers for Disease Control and Prevention; CHMP; Committee for Medicinal Products for Human Use; EGA; estimated gestational age; G
Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents
Keywords: کمیته دارویی برای استفاده انسانی; AE; adverse event; AS; Adjuvant System; AS03; tocopherol oil-in-water emulsion based Adjuvant System; ATP; according to protocol; BS; blood sampling; CHMP; Committee for Medicinal Products for Human Use; CI; confidence interval; EMA; European Medicines Ag
Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants
Keywords: کمیته دارویی برای استفاده انسانی; European Medicines Agency; EMEA; Committee for Medicinal Products for Human Use; CHMP; Antidepressants; Major depression; Drug evaluation
If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
Keywords: کمیته دارویی برای استفاده انسانی; CHMP; Committee for Medicinal Products for Human Use; COX; Cycloxygenase; ECG; Electrocardiogram; EU; European Union; FDA; Food and Drug Administration of the United States; hERG; Human ether-a-go-go related gene; ICH; International Conference on Harmoniz